Chrysin also decreases VEGF and HIF‐1α expression in metastatic prostate cancer cells in hypoxia (Han et al. 2022); however, its clinical application may be limited by poor systemic bioavailability (Gao et al. 2021). Here, VEGFA is linked to prostate carcinoma.